Guardant Health

Guardant Health is a leading precision oncology company dedicated to helping patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock— from informing treatment decisions for patients with advanced cancer, to monitoring recurrence in cancer survivors, and screening to find cancer at its earliest and most treatable stage in the general population. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests to support patients with advanced-stage cancer, and Guardant Reveal™ for survivors of early-stage cancer. Guardant Health’s breakthroughs in oncology have powered it’s screening portfolio, including the Shield™ blood test for the detection of colorectal cancer, which aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.